Targeting sphingosine-1-phosphate pathway with orally available immune-modulatory fingolimod (Gilenya™) therapy ameliorates relapsing-remitting multiple sclerosis (RRMS) by decreasing relapse rate as shown in FREEDOMS and TRANSFORMS. Fingolimod has also been shown to be superior to interferon-beta therapy as evidenced by TRANSFORMS. Albeit multiple benefits in treatment of multiple sclerosis in...

Lower levels of N-acetylaspartate (NAA), a marker of axonal damage, have been found in the normal-appearing white matter (NAWM) of relapsing-remitting multiple sclerosis (RRMS) patients with low physical disability. However, its relation to the clinical status of these patients remains unclear. We explored the association between NAA levels [normalized to creatine (Cr), NAA/Cr] and a cognitive ...

Introduction Evaluating the impact of health technology assessment (HTA) is vital to measure its contribution and social care decision-making improving citizen outcomes. Health Technology Wales (HTW) a HTA body committed evaluating our work. Here we present HTW’s evaluation approach with case study for autologous hematopoietic stem cell transplantation (AHSCT) highly active relapsing remitting ...

Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease of the central nervous system. Now 2.8 million people in world suffer from MS, since 2000 every 5 years there has been an increase number MS patients by 10%. At same time, cases with highly active (HAMS) increasing, i.e. two or more exacerbations without taking specific pathogenetic therapy ...

Introduction/Objectives: To analyse the infl uence of shortand long-term glatiramer acetate (GA) treatment on expression patterns of cell surfacebound adhesion molecules (AM) on peripheral blood mononuclear cells (PBMC) from patients with relapsing remitting multiple sclerosis (RRMS). BACKGROUND: GA is baseline therapy for the treatment of RRMS. It is known to reduce relapse frequencies and to ...

Multipl sklerozda (MS) santral sinir sistemi tutulması ön planda olduğu için perferik iletimi çalışmalarında herhangi bir anormallik beklenmez. Ancak literatürde MS'li hastalarda periferik iletim çalışmaları anormallikleri destekleyen çalışmalarda vardır. Bizim bu çalışmadaki amacımız Relapsing-Remitting formdaki (RRMS) tutulumunun olup olmadığını, ile ortaya koymaktır. 2001 yılında revize edil...

Introduction Since the development of coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome type 2 (SARS-CoV-2), there has been significant interest in determining effectiveness SARS-CoV-2 vaccines patients under immunomodulatory or immunosuppressive therapies. The aim this study was to evaluate impact ocrelizumab, a monoclonal anti-CD20 antibody, on SARS-CoV-2-spe...

Multiple sclerosis (MS) is an inflammatory disease that affects the central nervous system. MicroRNAs (miRNAs) are small non-coding RNAs that are usually 18-24 nucleotides long, which may have a pivotal role in the expansion of many complex diseases. The objective of this study was to evaluate the transcript levels of miR-193b-3p and miR-376a-3p in relapsing-remitting multiple sclerosis (RRMS) ...

Interferon beta (IFN-β) therapy is one of the most commonly prescribed immunomodulatory therapies in relapsing-remitting multiple sclerosis (RRMS). A reversible cerebral vasoconstriction syndrome (RCVS), associated with IFN-β use, has been recently described. For this reason, we tested the effect of once a week intramuscular administration of IFN-β-1A on the function of cerebral vessels in a co...